SCHEMBL12880533

SCHEMBL12880533

CN1CCN(Cc2cc(F)ccc2Cc2cnc(-c3nc4ccc(N5CCOCC5)cn4c(=O)c3O)s2)S1(=O)=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.34
CSNK1D P48730 2/20 0.34
CSNK1E P49674 2/20 0.34
PIK3CA P42336 2/20 0.34
MTOR P42345 2/20 0.34
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ENPP2 Q13822 1/20 0.33
CYP1A2 P05177 2/20 0.33
ALDH1A1 P00352 2/20 0.33
TSHR P16473 2/20 0.33
CASP1 P29466 2/20 0.33
CASP7 P55210 2/20 0.33
HIF1A Q16665 2/20 0.33
GLA P06280 1/20 0.33
CYP3A4 P08684 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GRIA2 P42262 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2A Q12879 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12880531 0.90 SLC2A1 (0.34) SLC2A1CSNK1DCSNK1EPIK3CAMTOR
SCHEMBL12880535 0.89 LMNA (0.40) SLC2A1CSNK1DCSNK1EPIK3CAMTOR
SCHEMBL13512869 0.88 SLC2A1 (0.33) SLC2A1CSNK1DCSNK1EPIK3CAMTOR
SCHEMBL12880534 0.87 ENPP2 (0.38) SLC2A1CSNK1DCSNK1EPIK3CAMTOR
SCHEMBL12880542 0.85 IDO1 (0.37) SLC2A1CSNK1DCSNK1EPIK3CAMTOR
SCHEMBL12880529 0.83 PIK3CA (0.37) SLC2A1CSNK1DCSNK1EPIK3CAMTOR
SCHEMBL12894068 0.83 JAK2 (0.38) SLC2A1CSNK1DCSNK1EPIK3CAMTOR
SCHEMBL12880536 0.82 KMT2A (0.38) SLC2A1CSNK1DCSNK1EPIK3CALMNA
SCHEMBL12880527 0.82 JAK2 (0.38) SLC2A1CSNK1DCSNK1EPIK3CAMTOR
SCHEMBL12880532 0.82 SLC2A1 (0.33) SLC2A1CSNK1DCSNK1EPIK3CAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318732-B2 Compounds having antiviral properties AVEXA LIMITED (AU) 2012-11-27 US disclosed
US-8318732-B2 Compounds having antiviral properties AVEXA LIMITED (AU) 2012-11-27 US disclosed
US-20110039842-A1 COMPOUNDS HAVING ANTIVIRAL PROPERTIES AVEXA LIMITED (AU) 2011-02-17 US disclosed
US-20110039842-A1 COMPOUNDS HAVING ANTIVIRAL PROPERTIES AVEXA LIMITED (AU) 2011-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039842-A1 COMPOUNDS HAVING ANTIVIRAL PROPERTIES ZC3HAV1, ACE, EIF2AK2 SLC2A1 751/4885CSNK1D 889/4885CSNK1E 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.